

Jubilant Life Sciences International Pte. Limited
Balance Sheet as at 31 March 2024

		USD	INR (In Thousands)	USD	INR (In Thousands)
	Notes	As at 31 March 2024		As at 31 March 2023	
ASSETS					
Non-current assets					
Financial assets					
Investments	1	200,000	16,681	200,000	16,434
Loans and advances	2	19,203,701	1,601,685	19,203,761	1,577,973
Total non-current assets		19,403,701	1,618,366	19,403,761	1,594,407
Current assets					
Financial assets					
Cash and cash equivalents	3	2,356,558	196,549	1,639,635	134,729
Other financial assets	4	137,514	11,469	137,514	11,300
Total current assets		2,494,072	208,018	1,777,149	146,029
Total assets		21,897,773	1,826,384	21,180,910	1,740,436
EQUITY AND LIABILITIES					
Equity					
Equity share capital	5	437,503	19,990	437,503	19,990
Other equity		21,446,988	1,805,286	20,730,112	1,719,353
Total equity		21,884,491	1,825,276	21,167,615	1,739,343
LIABILITIES					
Current liabilities					
Financial liabilities					
Trade payables	6	7,394	617	7,884	648
Current tax liabilities	7	5,888	491	5,411	445
Total current liabilities		13,282	1,108	13,295	1,093
Total liabilities		13,282	1,108	13,295	1,093
Total equity and liabilities		21,897,773	1,826,384	21,180,910	1,740,436

SS Hariharasubramaniam
Sr. Director – Accounts
Place: Noida
Date: 10 May 2024

Jubilant Life Sciences International Pte. Limited
Statement of Profit and Loss for the year ended 31 March 2024

Particulars	Notes	USD	INR (In Thousands)	USD	INR (In Thousands)
		For the year ended 31 March 2024		For the year ended 31 March 2023	
Other income	8	782,197	64,744	768,000	61,678
Total income		782,197	64,744	768,000	61,678
Expenses					
Other expenses	9	24,484	2,026	14,613	1,170
Total expenses		24,484	2,026	14,613	1,170
Profit before tax		757,713	62,718	753,387	60,508
Tax expense					
- Current tax		40,837	3,391	59,023	4,851
- Deferred tax		-	-	(44,124)	(3,406)
Total tax expense		40,837	3,391	14,899	1,445
Profit after tax		716,876	59,327	738,488	59,063
Other comprehensive income					
Equity Instrument through Other comprehensive income		-	-	-	-
<i>Items that will not be reclassified to profit or loss</i>					
Exchange differences on translation of foreign operations		-	26,606	-	131,906
Other comprehensive income/(loss) for the year, net of tax		-	26,606	-	131,906
Total comprehensive income/(loss) for the year		716,876	85,933	738,488	190,969

SS Hariharasubramaniam
Sr. Director – Accounts
Place: Noida
Date: 10 May 2024

Jubilant Life Sciences International Pte. Limited
Statement of changes in Equity for the year ended 31st March 2024

A. Equity share capital

	USD	INR (In Thousands)
Balance as at 1 April 2022	437,503	19,990
Changes in equity share capital during the year	-	-
Balance as at 31 March 2023	437,503	19,990
Changes in equity share capital during	-	-
Balance as at 31 March 2024	437,503	19,990

B. Other equity

	Reserves and surplus								
	Retained earnings		Equity Instrument through OCI		Capital Reserve		Exchange differences on translation of foreign operations	Total	
	USD	INR (In Thousands)	USD	INR (In Thousands)	USD	INR (In Thousands)	INR (In Thousands)	USD	INR (In Thousands)
Balance as at 1 April 2022	1,398,962	96,967	11,534,992	841,666	7,057,670	473,429	116,322	19,991,624	1,528,384
Profit for the year	738,488	59,063					-	738,488	59,063
Exchange differences on translation of foreign operations	-	-	-	-	-	-	131,906	-	131,906
Balance as at 31 March 2023	2,137,450	156,030	11,534,992	841,666	7,057,670	473,429	248,228	20,730,112	1,719,353
Balance as at 1 April 2023	2,137,450	156,030	11,534,992	841,666	7,057,670	473,429	248,228	20,730,112	1,719,353
Profit for the year	716,876	59,327					-	716,876	59,327
Exchange differences on translation of foreign operations	-	-	-	-	-	-	26,606	-	26,606
Balance as at 31 March 2024	2,854,326	215,357	11,534,992	841,666	7,057,670	473,429	274,834	21,446,988	1,805,286

SS Hariharasubramaniam
Sr. Director – Accounts
Place: Noida
Date: 10 May 2024

Jubilant Life Sciences International Pte. Limited
Statement of Cash Flows for the year ended 31 March 2024

Particulars	USD	INR (In Thousands)	USD	INR (In Thousands)
	For the year ended 31 March 2024		For the year ended 31 March 2023	
A. Cash flow from operating activities				
Net profit before tax	757,713	62,718	753,387	60,508
Adjustments :				
Interest Income	(782,197)	(64,744)	(768,000)	(61,678)
Operating cash flow before working capital changes	(24,484)	(2,026)	(14,613)	(1,170)
Decrease/ (increase) in other current assets and loan and	60	5	(68)	(6)
Decrease in trade payables and current liabilities	(490)	(41)	(8,924)	(716)
Cash used in operations	(24,914)	(2,062)	(23,605)	(1,892)
Income tax paid (net of refund)	(40,360)	(3,340)	(54,147)	(4,346)
Net cash (used) in operating activities	(65,274)	(5,402)	(77,752)	(6,238)
B. Cash flow from investing activities				
Interest Received	782,197	64,744	1,047,764	84,099
Net cash generated from investing activities	782,197	64,744	1,047,764	84,099
C. Effect of exchange rate changes	-	2,478	-	6,116
Net increase in cash and cash equivalents (A+B+C)	716,923	61,820	970,012	83,977
Add: cash and cash equivalents at the beginning of year	1,639,635	134,729	669,623	50,752
Cash and cash equivalents at the end of the year	2,356,558	196,549	1,639,635	134,729

SS Hariharasubramaniam

Sr. Director – Accounts

Place: Noida

Date: 10 May 2024

Jubilant Life Sciences International Pte. Limited
Notes to the financial statements for the year ended 31 March 2024

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2024		As at 31 March 2023	
Note 1. Non-current investments				
Investment in subsidiaries				
Investment in Jubilant Life Sciences (Shanghai) Limited 200,000 (31 March 2023:200,000 equity share of USD 1 each)	200,000	16,681	200,000	16,434
	200,000	16,681	200,000	16,434
Note 2. Long term loan and advances				
Security deposits	3,701	309	3,761	309
Loans to related parties	19,200,000	1,601,376	19,200,000	1,577,664
	19,203,701	1,601,685	19,203,761	1,577,973
Note 3. Cash and cash equivalent				
Balances with banks:				
- On current accounts	892,361	74,427	1,639,635	134,729
- On deposit accounts	1,464,197	122,122	-	-
	2,356,558	196,549	1,639,635	134,729
Note 4. Other financial assets				
Advance and interest recoverable-related party	137,514	11,469	137,514	11,300
	137,514	11,469	137,514	11,300

Jubilant Life Sciences International Pte. Limited
Statement of changes in Equity for the year ended 31st March 2024

Note 5: Equity share capital

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2024		As at 31 March 2023	
Issued, subscribed and paid up share capital				
437,503 (31 March 2023: 437,503 Equity shares with no par value)	437,503	19,990	437,503	19,990
	437,503	19,990	437,503	19,990

1). Movement in Equity share capital

	No. of shares	USD	INR (In Thousands)
Balance as at 1 April 2022	437,503	437,503	19,990
Changes in equity share capital during the year	-	-	-
Balance as at 31 March 2023	437,503	437,503	19,990
Changes in equity share capital during the year	-	-	-
Balance as at 31 March 2024	437,503	437,503	19,990

2) Terms and rights attached to equity shares

The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

3) The details of shareholders holding more than 5% shares in the company

	As at 31 March 2024		As at 31 March 2023	
	No. of shares	% holding in the class	No. of shares	% holding in the class
Name of the Shareholder				
Jubilant Ingrevia Limited	437,503	100%	437,503	100%

Jubilant Life Sciences International Pte. Limited
Notes to the financial statements for the year ended 31 March 2024

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2024		As at 31 March 2023	
Note 6. Trade payables				
Trade payables	7,394	617	7,884	648
	7,394	617	7,884	648
Note 7. Current tax liabilities				
Provision for income tax	5,888	491	5,411	445
	5,888	491	5,411	445
Note 8. Other income				
	For the year ended 31 March 2024		For the year ended 31 March 2023	
Interest Income	782,197	64,744	768,000	61,678
	782,197	64,744	768,000	61,678
Note 9. Other expenses				
Auditors remuneration	6,696	554	7,065	568
Legal, professional and consultancy charges	17,086	1,414	6,862	548
Bank charges	643	53	754	60
Foreign exchange loss/ (gain)	59	5	(68)	(6)
	24,484	2,026	14,613	1,170